{
    "hands_on_practices": [
        {
            "introduction": "A cornerstone of diagnosing and staging Vascular Cognitive Impairment (VCI) is the accurate quantification of cerebral small vessel disease from neuroimaging. Standardized visual rating scales provide a reliable and widely used method for assessing the burden of white matter hyperintensities (WMH) on Magnetic Resonance Imaging (MRI). This practice will develop your foundational skill in applying the Fazekas and Age-Related White Matter Changes (ARWMC) scales, which are essential tools in both clinical practice and research for grading the severity of cerebrovascular disease .",
            "id": "4534526",
            "problem": "A $72$-year-old individual with longstanding hypertension undergoes brain Magnetic Resonance Imaging (MRI) including axial Fluid-Attenuated Inversion Recovery (FLAIR) sequences for evaluation of cognitive slowing and executive dysfunction. You are asked to quantify white matter disease severity relevant to vascular cognitive impairment using the Fazekas scales and the Age-Related White Matter Changes (ARWMC) scale.\n\nUse the following standard categorical definitions as the foundational base:\n\n- Fazekas periventricular rating (periventricular hyperintensities adjacent to the lateral ventricles): $0$ absent, $1$ caps or pencil-thin lining, $2$ smooth halo, $3$ irregular periventricular hyperintensity extending into deep white matter.\n- Fazekas deep white matter rating (lesions in deep and subcortical white matter excluding the periventricular rim): $0$ absent, $1$ punctate foci, $2$ beginning confluence of foci, $3$ large confluent areas.\n- Age-Related White Matter Changes (ARWMC) scale: score each hemisphere in five regions—frontal, parieto-occipital, temporal, infratentorial, and basal ganglia—on a $0$–$3$ scale. For lobar and infratentorial white matter: $0$ no lesions, $1$ focal lesions, $2$ beginning confluence, $3$ diffuse involvement of the entire region with or without involvement of U-fibers. For basal ganglia: $0$ no lesion, $1$ one focal lesion, $2$ more than one focal lesion, $3$ confluent lesions.\n\nAxial FLAIR findings are described as follows:\n\n- Periventricular region: symmetric hyperintense “caps” at the frontal horns and occipital horns with a pencil-thin periventricular lining along the bodies of the lateral ventricles; no smooth halo and no irregular extension into the deep white matter are present.\n- Deep and subcortical white matter: in the bilateral centrum semiovale, there are large confluent areas of FLAIR hyperintensity where multiple foci have merged into broad plaques spanning more than $20$ mm, bridging adjacent foci and involving long tracts; these areas are not confined to U-fibers.\n- ARWMC regional description:\n\nLeft hemisphere:\n- Frontal white matter: diffuse involvement across most of the lobe with involvement of U-fibers.\n- Parieto-occipital white matter: beginning confluence of multiple lesions.\n- Temporal white matter: a few distinct focal hyperintense foci without confluence.\n- Infratentorial white matter (brainstem and cerebellar white matter): no hyperintense lesions.\n- Basal ganglia region (including caudate, putamen, globus pallidus, internal capsule, thalamus): two discrete hyperintense foci without confluence.\n\nRight hemisphere:\n- Frontal white matter: beginning confluence of multiple lesions.\n- Parieto-occipital white matter: a single focal hyperintense lesion.\n- Temporal white matter: no lesions.\n- Infratentorial white matter: no lesions.\n- Basal ganglia region: one focal hyperintense lesion without confluence.\n\nFrom these descriptions, compute:\n- the Fazekas periventricular score, denoted $F_{PV}$,\n- the Fazekas deep white matter score, denoted $F_{DWM}$,\n- and the total ARWMC sum score across both hemispheres and all regions, denoted $S_{ARWMC}$.\n\nExpress your final answer as a row matrix in the order $\\left(F_{PV}, F_{DWM}, S_{ARWMC}\\right)$. No rounding is required. Do not include units in the final answer.",
            "solution": "The problem requires the quantification of white matter disease severity from described Magnetic Resonance Imaging (MRI) findings using two standard radiological scales: the Fazekas scale and the Age-Related White Matter Changes (ARWMC) scale. The solution involves a systematic application of the provided scoring rules to the descriptive findings.\n\nWe are asked to compute three values: the Fazekas periventricular score ($F_{PV}$), the Fazekas deep white matter score ($F_{DWM}$), and the total ARWMC score ($S_{ARWMC}$).\n\n**1. Calculation of the Fazekas Periventricular Score ($F_{PV}$)**\n\nThe Fazekas periventricular rating system is defined as:\n- $0$: absent\n- $1$: caps or pencil-thin lining\n- $2$: smooth halo\n- $3$: irregular periventricular hyperintensity extending into deep white matter\n\nThe provided MRI finding for the periventricular region is: \"symmetric hyperintense 'caps' at the frontal horns and occipital horns with a pencil-thin periventricular lining along the bodies of the lateral ventricles; no smooth halo and no irregular extension into the deep white matter are present.\"\n\nThis description, \"caps or pencil-thin lining,\" corresponds directly to the definition for a score of $1$. The explicit exclusion of findings for scores $2$ and $3$ confirms this assessment.\nTherefore, the Fazekas periventricular score is $1$.\n$$F_{PV} = 1$$\n\n**2. Calculation of the Fazekas Deep White Matter Score ($F_{DWM}$)**\n\nThe Fazekas deep white matter rating system is defined as:\n- $0$: absent\n- $1$: punctate foci\n- $2$: beginning confluence of foci\n- $3$: large confluent areas\n\nThe provided MRI finding for the deep and subcortical white matter is: \"in the bilateral centrum semiovale, there are large confluent areas of FLAIR hyperintensity where multiple foci have merged into broad plaques spanning more than $20$ mm...\"\n\nThis description, \"large confluent areas,\" directly corresponds to the definition for a score of $3$.\nTherefore, the Fazekas deep white matter score is $3$.\n$$F_{DWM} = 3$$\n\n**3. Calculation of the Total ARWMC Score ($S_{ARWMC}$)**\n\nThe ARWMC scale requires scoring five regions in each hemisphere and summing the results. The scoring criteria differ for lobar/infratentorial regions and the basal ganglia.\n\nThe scale for lobar (frontal, parieto-occipital, temporal) and infratentorial white matter is:\n- $0$: no lesions\n- $1$: focal lesions\n- $2$: beginning confluence\n- $3$: diffuse involvement\n\nThe scale for the basal ganglia is:\n- $0$: no lesion\n- $1$: one focal lesion\n- $2$: more than one focal lesion\n- $3$: confluent lesions\n\nWe will score each region for both hemispheres.\n\n**Left Hemisphere:**\n- Frontal: \"diffuse involvement across most of the lobe with involvement of U-fibers.\" This matches the lobar scale definition for a score of $3$.\n- Parieto-occipital: \"beginning confluence of multiple lesions.\" This matches the lobar scale definition for a score of $2$.\n- Temporal: \"a few distinct focal hyperintense foci without confluence.\" This corresponds to \"focal lesions,\" yielding a score of $1$.\n- Infratentorial: \"no hyperintense lesions.\" This yields a score of $0$.\n- Basal ganglia: \"two discrete hyperintense foci without confluence.\" This corresponds to \"more than one focal lesion\" on the basal ganglia scale, yielding a score of $2$.\n\nThe total score for the left hemisphere is the sum of these regional scores:\n$$S_{Left} = 3 + 2 + 1 + 0 + 2 = 8$$\n\n**Right Hemisphere:**\n- Frontal: \"beginning confluence of multiple lesions.\" This matches the lobar scale definition for a score of $2$.\n- Parieto-occipital: \"a single focal hyperintense lesion.\" This corresponds to \"focal lesions\" (even if singular, it's not absent or confluent), yielding a score of $1$.\n- Temporal: \"no lesions.\" This yields a score of $0$.\n- Infratentorial: \"no lesions.\" This yields a score of $0$.\n- Basal ganglia: \"one focal hyperintense lesion without confluence.\" This matches the basal ganglia scale definition for a score of $1$.\n\nThe total score for the right hemisphere is the sum of these regional scores:\n$$S_{Right} = 2 + 1 + 0 + 0 + 1 = 4$$\n\nThe total ARWMC sum score, $S_{ARWMC}$, is the sum of the scores from both hemispheres:\n$$S_{ARWMC} = S_{Left} + S_{Right} = 8 + 4 = 12$$\n\nThus, the three computed values are $F_{PV} = 1$, $F_{DWM} = 3$, and $S_{ARWMC} = 12$. The final answer is expressed as a row matrix $(F_{PV}, F_{DWM}, S_{ARWMC})$.",
            "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n1 & 3 & 12\n\\end{pmatrix}\n}\n$$"
        },
        {
            "introduction": "Clinicians often face complex cases where the severity of cognitive impairment does not seem to match the burden of disease seen on conventional in-vivo imaging. This exercise presents such a scenario, challenging you to reconcile severe dementia with only modest white matter disease by integrating \"ground truth\" neuropathological findings . This practice hones high-level diagnostic reasoning by demonstrating that multiple, sometimes MRI-invisible, pathologies like microinfarcts and synaptic loss often co-exist and contribute additively to a patient's final clinical state.",
            "id": "4534529",
            "problem": "An autopsy-based case series reports a patient who, during life, had severe global cognitive impairment despite modest white matter hyperintensities. The subject was a $82$-year-old right-handed person with $3$ years of progressive decline. Neuropsychological testing $6$ months prior to death showed Montreal Cognitive Assessment (MoCA) score $12/30$, Clinical Dementia Rating (CDR) global score $2$ with Sum of Boxes $10$, and executive impairment with Trail Making Test Part B completion time $240$ seconds. Magnetic Resonance Imaging (MRI) performed $1$ year prior showed a Fazekas white matter hyperintensity (WMH) score of $1$, total WMH volume of approximately $10$ milliliters, $0$ lacunes, and $3$ cortical microbleeds. Hippocampal volumetry was $-2$ standard deviations below age norms. Amyloid positron emission tomography (PET) was negative. The subject died of pneumonia; neuropathology revealed the following: $45$ cortical microinfarcts distributed across association cortices and subcortical nuclei; bilateral hippocampal sclerosis with cornu ammonis area $1$ neuronal loss estimated at $60\\%$ and gliosis; and reduced synaptophysin immunoreactivity consistent with approximately $35\\%$ reduction in synaptic density in frontal and parietal cortex. Beta-amyloid (Thal phase $1$) and tau neurofibrillary pathology (Braak stage $II$) were minimal, and Lewy body pathology was absent.\n\nUsing only core definitions and well-tested facts as your starting point, reason which explanation best reconciles the severe cognitive impairment with the modest WMH burden. Your reasoning must begin from the following principles without introducing any special-case formulas or shortcuts in the problem statement:\n\n- Distributed cognitive functions depend on intact long-range white matter tracts and local synaptic connectivity; damage to either reduces the capacity of networks to integrate information.\n- Microinfarcts are small ischemic lesions often below the resolution of conventional MRI and can disrupt cortical columns and short-range association fibers.\n- Hippocampal sclerosis involves neuron loss and gliosis in hippocampal subfields critical for episodic memory encoding and retrieval, with downstream effects on distributed networks.\n- Quantitative neuropathology shows that synaptic density loss correlates strongly with cognitive impairment across domains, and multiple independent pathologies can have additive effects on functional capacity.\n\nWhich option most plausibly and mechanistically accounts for this patient’s severe global cognitive impairment despite modest WMH?\n\nA. The combined impact of widespread cortical microinfarcts (invisible to conventional MRI), bilateral hippocampal sclerosis, and cortical synaptic loss reduces distributed network capacity across memory and executive systems, producing severe impairment even when WMH burden is modest.\n\nB. Because WMH are modest, vascular contributions are negligible; severe impairment must be explained by an Alzheimer disease process, and microinfarcts and synaptic loss are likely incidental age-related findings.\n\nC. The discrepancy is best explained by systematic underestimation of WMH volume on MRI due to partial volume effects, so there is no need to invoke microinfarcts, hippocampal sclerosis, or synaptic loss as contributors.\n\nD. The microbleed count alone is sufficient to explain severe global deficits by causing diffuse neuronal death; other pathologies are not required to reconcile the severity of impairment.",
            "solution": "The problem statement will first be validated for scientific soundness, completeness, and objectivity.\n\n**Step 1: Extract Givens**\n\n*   **Subject Profile**: $82$-year-old right-handed person.\n*   **Clinical Course**: $3$ years of progressive cognitive decline.\n*   **Neuropsychological Data ($6$ months pre-mortem)**:\n    *   Montreal Cognitive Assessment (MoCA): $12/30$.\n    *   Clinical Dementia Rating (CDR) Global Score: $2$.\n    *   CDR Sum of Boxes (CDR-SB): $10$.\n    *   Trail Making Test Part B (TMT-B): $240$ seconds.\n*   **Magnetic Resonance Imaging (MRI) Data ($1$ year pre-mortem)**:\n    *   Fazekas white matter hyperintensity (WMH) score: $1$.\n    *   Total WMH volume: approximately $10$ milliliters.\n    *   Lacunes: $0$.\n    *   Cortical microbleeds: $3$.\n    *   Hippocampal volumetry: $-2$ standard deviations below age norms.\n*   **Positron Emission Tomography (PET) Data**:\n    *   Amyloid PET: Negative.\n*   **Neuropathology Findings**:\n    *   Cortical microinfarcts: $45$, distributed across association cortices and subcortical nuclei.\n    *   Hippocampal sclerosis: Bilateral, with cornu ammonis area $1$ (CA1) neuronal loss estimated at $60\\%$ and gliosis.\n    *   Synaptic density: Approximately $35\\%$ reduction in synaptic density in frontal and parietal cortex (inferred from reduced synaptophysin immunoreactivity).\n    *   Beta-amyloid pathology: Thal phase $1$ (minimal).\n    *   Tau neurofibrillary pathology: Braak stage $II$ (minimal).\n    *   Lewy body pathology: Absent.\n*   **Governing Principles**:\n    1.  Distributed cognitive functions depend on intact long-range white matter tracts and local synaptic connectivity; damage reduces network capacity.\n    2.  Microinfarcts are small, often MRI-invisible ischemic lesions that disrupt cortical and subcortical function.\n    3.  Hippocampal sclerosis involves neuron loss and gliosis critical for memory, with network-wide effects.\n    4.  Synaptic density loss strongly correlates with cognitive impairment; multiple pathologies can have additive effects.\n\n**Step 2: Validate Using Extracted Givens**\n\nThe problem presents a detailed clinico-pathological case study. The validation is as follows:\n\n*   **Scientifically Grounded**: The problem is firmly grounded in established neurology and neuropathology. The clinical scores (MoCA, CDR), imaging findings (Fazekas, lacunes, microbleeds, hippocampal atrophy), and neuropathological measures (microinfarcts, hippocampal sclerosis, synaptic loss, Thal/Braak stages) are standard in the field of dementia research. The presented values are realistic: MoCA $12/30$ and CDR $2$ indicate moderate-to-severe dementia, while a Fazekas score of $1$ indicates mild WMH. The core discrepancy between mild large-vessel disease markers (WMH) and severe clinical impairment is a well-documented phenomenon. The negative amyloid PET and low levels of Alzheimer's pathology at autopsy are consistent with each other and point towards a non-Alzheimer's etiology. The case is a classic representation of suspected non-AD underlying pathophysiology (SNAP) with significant vascular and other neurodegenerative contributions. The provided principles are foundational tenets of cognitive neuroscience.\n*   **Well-Posed**: The problem is well-posed. It provides a comprehensive dataset (clinical, imaging, pathology) and asks for the most plausible explanation reconciling these findings, based on a given set of principles. A unique and meaningful solution can be derived by logical application of these principles to the data.\n*   **Objective**: The problem is stated using objective, quantitative data and standard clinical/pathological terminology. It is free from subjective or biased language.\n\n**Step 3: Verdict and Action**\n\nThe problem statement is **valid**. It is a scientifically sound, well-posed, and objective problem. The solution process may proceed.\n\n**Derivation of Solution**\n\nThe central task is to explain the severe global cognitive impairment (MoCA $12/30$, CDR $2$) in a patient with only modest white matter hyperintensities (Fazekas $1$). The solution must be derived from the provided principles and pathological findings.\n\n1.  **Analyze the Discrepancy**: The modest WMH burden, a marker of large-vessel small vessel disease, is insufficient by itself to account for severe dementia. This directs the investigation toward other pathologies revealed by the autopsy.\n\n2.  **Evaluate Pathological Contributions based on Principles**:\n    *   **Alzheimer's Disease (AD)**: The negative amyloid PET and minimal AD pathology at autopsy (Thal phase $1$, Braak stage $II$) effectively rule out AD as the primary cause of the severe dementia.\n    *   **Lewy Body Disease**: The absence of Lewy body pathology rules this out.\n    *   **Hippocampal Sclerosis**: The finding of bilateral hippocampal sclerosis with $60\\%$ neuronal loss in CA1 is a severe pathology. According to Principle 3, this pathology is critical for episodic memory. The significant atrophy seen on MRI ($-2$ SD) is the macroscopic sign of this neuronal loss. This finding robustly explains the severe memory deficits that are a major component of global cognitive impairment.\n    *   **Cortical Microinfarcts**: The autopsy revealed $45$ cortical microinfarcts. Principle 2 states these are often invisible on conventional MRI and disrupt cortical function. Their presence in association cortices, which are crucial for higher-order cognition including executive function, would significantly contribute to the patient's impairment (e.g., TMT-B time of $240$s). The large number of these lesions suggests a widespread disruption of cortical micro-circuitry.\n    *   **Synaptic Loss**: The $35\\%$ reduction in synaptic density in frontal and parietal cortex is a profound pathology. According to Principle 4, synaptic loss is a strong correlate of cognitive impairment across all domains. According to Principle 1, this loss directly degrades the capacity of neural networks to process and integrate information. This finding provides a fundamental substrate for the global nature of the cognitive decline.\n\n3.  **Synthesize the Findings**: The severe cognitive impairment is not caused by a single pathology but by the additive effect of multiple, co-existing pathologies, as stated in Principle 4. The \"modest\" imaging finding of WMH is misleading. The true burden of brain injury includes:\n    *   Widespread cerebrovascular disease at the micro-level (i.e., $45$ microinfarcts), not captured by WMH grading.\n    *   A severe, focal neurodegenerative process (bilateral hippocampal sclerosis).\n    *   A diffuse loss of the fundamental units of neural communication (synaptic loss).\n\n    The combination of these three severe pathologies—each affecting different components of the brain's functional architecture (cortical microcircuits, limbic memory system, synaptic integrity)—provides a comprehensive and mechanistic explanation for the severe, global cognitive impairment.\n\n**Evaluation of Options**\n\n*   **A. The combined impact of widespread cortical microinfarcts (invisible to conventional MRI), bilateral hippocampal sclerosis, and cortical synaptic loss reduces distributed network capacity across memory and executive systems, producing severe impairment even when WMH burden is modest.**\n    *   This statement accurately synthesizes the key neuropathological findings (microinfarcts, hippocampal sclerosis, synaptic loss). It correctly attributes the cognitive impairment to the combined, additive effects of these pathologies, consistent with Principle 4. It correctly identifies that these pathologies affect distributed networks for memory and executive function, consistent with Principles 1, 2, and 3. This option provides the most complete and accurate explanation for the entire clinical-pathological picture.\n    *   **Verdict: Correct.**\n\n*   **B. Because WMH are modest, vascular contributions are negligible; severe impairment must be explained by an Alzheimer disease process, and microinfarcts and synaptic loss are likely incidental age-related findings.**\n    *   This statement contains multiple falsehoods. First, it incorrectly equates vascular contributions with WMH alone, ignoring the $45$ microinfarcts, which are a form of vascular injury. Therefore, vascular contributions are *not* negligible. Second, it incorrectly invokes Alzheimer's disease, which is explicitly ruled out by the negative amyloid PET and minimal AD pathology at autopsy. Third, it dismisses a $45$-lesion microinfarct burden and a $35\\%$ synaptic loss as \"incidental,\" which contradicts Principle 4 and established neuropathological evidence.\n    *   **Verdict: Incorrect.**\n\n*   **C. The discrepancy is best explained by systematic underestimation of WMH volume on MRI due to partial volume effects, so there is no need to invoke microinfarcts, hippocampal sclerosis, or synaptic loss as contributors.**\n    *   This option speculates about a methodological artifact on the MRI scan while ignoring the definitive \"ground truth\" data from the autopsy. While MRI measurements have limitations, it is illogical to dismiss multiple, severe, and directly observed pathologies in favor of an unproven and quantitatively implausible measurement error. The autopsy provides the explanation; there is no need to invent an alternative one based on MRI limitations.\n    *   **Verdict: Incorrect.**\n\n*   **D. The microbleed count alone is sufficient to explain severe global deficits by causing diffuse neuronal death; other pathologies are not required to reconcile the severity of impairment.**\n    *   This option incorrectly inflates the significance of a minor finding. A count of $3$ cortical microbleeds is very low and, while a marker of microangiopathy, is not considered sufficient on its own to cause severe global dementia. This option arbitrarily focuses on one minor detail while ignoring the far more substantial pathologies (microinfarcts, hippocampal sclerosis, synaptic loss) that were found.\n    *   **Verdict: Incorrect.**",
            "answer": "$$\\boxed{A}$$"
        },
        {
            "introduction": "Effective management of VCI centers on mitigating vascular risk factors to slow disease progression. To evaluate the success of such strategies, it is critical to quantify changes in brain health over time and model the impact of interventions. This problem provides hands-on practice in a core skill for clinical research: analyzing longitudinal imaging data to measure WMH progression and using linear regression to estimate the therapeutic effect of blood pressure reduction . Mastering this type of analysis is essential for critically interpreting and contributing to the evidence base for VCI treatment.",
            "id": "4534573",
            "problem": "A cohort of older adults with long-standing hypertension was followed to study the relationship between changes in systolic blood pressure (SBP) and progression of cerebral White Matter Hyperintensity (WMH) volume, a magnetic resonance imaging biomarker of small vessel ischemic disease associated with vascular cognitive impairment and vascular dementia. White Matter Hyperintensity (WMH) volumes were quantified in milliliters using Magnetic Resonance Imaging (MRI) at baseline and after two years, and achieved SBP reduction was recorded as the absolute decrease in millimeters of mercury (mmHg) from baseline to the average of repeated measures during the two-year follow-up. For participant $i$, denote baseline WMH volume by $V_{0,i}$, the two-year WMH volume by $V_{2,i}$, and the achieved SBP reduction by $\\Delta SBP_{i}$. The annualized WMH progression rate is defined as $$y_{i} = \\frac{V_{2,i} - V_{0,i}}{2}.$$\n\nAssume an ordinary least squares linear model $$y_{i} = \\beta_{0} + \\beta_{1} x_{i} + \\varepsilon_{i},$$ where $x_{i} = \\Delta SBP_{i}$ in mmHg, $y_{i}$ is in milliliters per year, and $\\varepsilon_{i}$ is a mean-zero random error term.\n\nUse the data below for $i=1,\\dots,6$:\n- Participant $1$: $V_{0,1} = 12.0$ mL, $V_{2,1} = 15.5$ mL, $\\Delta SBP_{1} = 5$ mmHg.\n- Participant $2$: $V_{0,2} = 15.0$ mL, $V_{2,2} = 18.0$ mL, $\\Delta SBP_{2} = 10$ mmHg.\n- Participant $3$: $V_{0,3} = 10.0$ mL, $V_{2,3} = 12.5$ mL, $\\Delta SBP_{3} = 15$ mmHg.\n- Participant $4$: $V_{0,4} = 17.0$ mL, $V_{2,4} = 19.0$ mL, $\\Delta SBP_{4} = 20$ mmHg.\n- Participant $5$: $V_{0,5} = 14.0$ mL, $V_{2,5} = 15.5$ mL, $\\Delta SBP_{5} = 25$ mmHg.\n- Participant $6$: $V_{0,6} = 16.0$ mL, $V_{2,6} = 17.0$ mL, $\\Delta SBP_{6} = 30$ mmHg.\n\nTasks:\n1. Compute the annualized WMH progression rate $y_{i}$ for each participant, in milliliters per year.\n2. Using ordinary least squares, estimate $\\beta_{1}$, the effect of each $1$ mmHg reduction in SBP on the annualized WMH progression rate. Provide the numerical value of $\\beta_{1}$.\n\nExpress the final numerical value of $\\beta_{1}$ in milliliters per year per millimeter of mercury (mL/year per mmHg) and round your answer to four significant figures.",
            "solution": "The problem statement is evaluated to be valid. It is scientifically grounded in a realistic clinical research scenario, mathematically well-posed, and all data and definitions required for a solution are provided in a clear and objective manner. There are no contradictions, ambiguities, or violations of fundamental principles. We may proceed with the solution.\n\nThe problem requires a two-step analysis. First, we must compute the annualized White Matter Hyperintensity (WMH) progression rate, $y_i$, for each of the $6$ participants. Second, we must use these rates along with the given changes in systolic blood pressure (SBP), $x_i$, to estimate the slope coefficient $\\beta_1$ of the specified linear model using ordinary least squares (OLS).\n\n**Task 1: Compute the annualized WMH progression rate $y_i$.**\n\nThe annualized WMH progression rate $y_i$ is defined as:\n$$y_{i} = \\frac{V_{2,i} - V_{0,i}}{2}$$\nwhere $V_{0,i}$ is the baseline WMH volume and $V_{2,i}$ is the WMH volume after $2$ years. The independent variable is the achieved SBP reduction, $x_i = \\Delta SBP_i$.\n\nWe calculate the $(x_i, y_i)$ data pairs for each participant $i=1, \\dots, 6$:\n- For participant $1$:\n$x_1 = 5$ mmHg\n$y_1 = \\frac{15.5 - 12.0}{2} = \\frac{3.5}{2} = 1.75$ mL/year\n\n- For participant $2$:\n$x_2 = 10$ mmHg\n$y_2 = \\frac{18.0 - 15.0}{2} = \\frac{3.0}{2} = 1.50$ mL/year\n\n- For participant $3$:\n$x_3 = 15$ mmHg\n$y_3 = \\frac{12.5 - 10.0}{2} = \\frac{2.5}{2} = 1.25$ mL/year\n\n- For participant $4$:\n$x_4 = 20$ mmHg\n$y_4 = \\frac{19.0 - 17.0}{2} = \\frac{2.0}{2} = 1.00$ mL/year\n\n- For participant $5$:\n$x_5 = 25$ mmHg\n$y_5 = \\frac{15.5 - 14.0}{2} = \\frac{1.5}{2} = 0.75$ mL/year\n\n- For participant $6$:\n$x_6 = 30$ mmHg\n$y_6 = \\frac{17.0 - 16.0}{2} = \\frac{1.0}{2} = 0.50$ mL/year\n\nOur data set for the linear regression consists of the following pairs $(x_i, y_i)$:\n$(5, 1.75)$, $(10, 1.50)$, $(15, 1.25)$, $(20, 1.00)$, $(25, 0.75)$, $(30, 0.50)$.\n\n**Task 2: Estimate $\\beta_1$ using ordinary least squares (OLS).**\n\nThe OLS estimate of the slope $\\beta_1$ in the simple linear regression model $y_i = \\beta_0 + \\beta_1 x_i + \\varepsilon_i$ is denoted by $\\hat{\\beta}_1$ and is calculated using the formula:\n$$ \\hat{\\beta}_1 = \\frac{n \\sum_{i=1}^{n} x_i y_i - (\\sum_{i=1}^{n} x_i)(\\sum_{i=1}^{n} y_i)}{n \\sum_{i=1}^{n} x_i^2 - (\\sum_{i=1}^{n} x_i)^2} $$\nwhere $n$ is the sample size, which is $n=6$.\n\nFirst, we compute the necessary sums from our data:\n- Sum of $x_i$:\n$$ \\sum_{i=1}^{6} x_i = 5 + 10 + 15 + 20 + 25 + 30 = 105 $$\n- Sum of $y_i$:\n$$ \\sum_{i=1}^{6} y_i = 1.75 + 1.50 + 1.25 + 1.00 + 0.75 + 0.50 = 6.75 $$\n- Sum of squares of $x_i$:\n$$ \\sum_{i=1}^{6} x_i^2 = 5^2 + 10^2 + 15^2 + 20^2 + 25^2 + 30^2 = 25 + 100 + 225 + 400 + 625 + 900 = 2275 $$\n- Sum of the products $x_i y_i$:\n$$ \\sum_{i=1}^{6} x_i y_i = (5)(1.75) + (10)(1.50) + (15)(1.25) + (20)(1.00) + (25)(0.75) + (30)(0.50) $$\n$$ \\sum_{i=1}^{6} x_i y_i = 8.75 + 15.00 + 18.75 + 20.00 + 18.75 + 15.00 = 96.25 $$\n\nNow, we substitute these sums into the formula for $\\hat{\\beta}_1$:\n$$ \\hat{\\beta}_1 = \\frac{6 \\times (96.25) - (105)(6.75)}{6 \\times (2275) - (105)^2} $$\n\nCalculate the numerator:\n$$ \\text{Numerator} = 577.5 - 708.75 = -131.25 $$\n\nCalculate the denominator:\n$$ \\text{Denominator} = 13650 - 11025 = 2625 $$\n\nNow, compute the value of $\\hat{\\beta}_1$:\n$$ \\hat{\\beta}_1 = \\frac{-131.25}{2625} = -0.05 $$\n\nThe value of the estimate is exactly $-0.05$. The units are the units of $y$ divided by the units of $x$, which is (mL/year) per mmHg. The problem requires the answer to be rounded to four significant figures. The first non-zero digit is $5$. To express the result with four significant figures, we must add three trailing zeros after the $5$.\n\nTherefore, the estimated effect $\\hat{\\beta}_1$, rounded to four significant figures, is $-0.05000$ mL/year per mmHg. This indicates that for each $1$ mmHg reduction in SBP, the model predicts a decrease of $0.05000$ mL/year in the rate of WMH progression.",
            "answer": "$$\\boxed{-0.05000}$$"
        }
    ]
}